Castle Biosciences (CSTL) EBIT: 2018-2025
Historic EBIT for Castle Biosciences (CSTL) over the last 8 years, with Sep 2025 value amounting to -$6.8 million.
- Castle Biosciences' EBIT fell 233.96% to -$6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$34.9 million, marking a year-over-year decrease of 3265.41%. This contributed to the annual value of $8.7 million for FY2024, which is 112.75% up from last year.
- As of Q3 2025, Castle Biosciences' EBIT stood at -$6.8 million, which was down 60.06% from -$4.3 million recorded in Q2 2025.
- Castle Biosciences' EBIT's 5-year high stood at $5.1 million during Q3 2024, with a 5-year trough of -$31.5 million in Q1 2023.
- For the 3-year period, Castle Biosciences' EBIT averaged around -$8.9 million, with its median value being -$5.7 million (2023).
- Per our database at Business Quant, Castle Biosciences' EBIT plummeted by 1,265.89% in 2021 and then surged by 171.58% in 2024.
- Castle Biosciences' EBIT (Quarterly) stood at -$15.2 million in 2021, then tumbled by 50.50% to -$22.8 million in 2022, then spiked by 75.22% to -$5.7 million in 2023, then surged by 171.58% to $4.0 million in 2024, then plummeted by 233.96% to -$6.8 million in 2025.
- Its last three reported values are -$6.8 million in Q3 2025, -$4.3 million for Q2 2025, and -$27.9 million during Q1 2025.